Connectivity maps for biosimilar drug discovery in venoms: The case of Gila Monster Venom and the anti-diabetes drug Byetta®

Toxicon

Volumn 69, Issue , 2013, Pages 160-167

  Aramadhaka, Lavakumar Reddy ^a   Prorock, Alyson ^a   Dragulev, Bojan ^a   Bao, Yongde ^a   Fox, Jay W ^a  

^a UNIVERSITY OF VIRGINIA   (United States)

Author keywords

Biosimilar drugs; Byetta ; Connectivity map; Drug discovery; Gila monster; Natural product libraries

Indexed keywords

ACTIVATING TRANSCRIPTION FACTOR 3; BIOSIMILAR AGENT; DEXAMETHASONE INDUCED RAS RELATED PROTEIN 1; EARLY GROWTH RESPONSE FACTOR 1; EXENDIN 4; HELODERMA SUSPECTUM VENOM; INTERLEUKIN 8; METFORMIN; NUCLEAR RECEPTOR NR4A3; RAS PROTEIN; SOMATOMEDIN C; TRANSCRIPTOME; TROGLITAZONE; UNCLASSIFIED DRUG; VENOM; 2,4 THIAZOLIDINEDIONE DERIVATIVE; ANTIDIABETIC AGENT; ATF3 PROTEIN, HUMAN; DNA BINDING PROTEIN; EGR1 PROTEIN, HUMAN; GLUCAGON LIKE PEPTIDE 1 RECEPTOR; GLUCAGON RECEPTOR; GLUCAGON-LIKE PEPTIDE-1 RECEPTOR; NR4A3 PROTEIN, HUMAN; PEPTIDE; RASD1 PROTEIN, HUMAN; STEROID RECEPTOR; THYROID HORMONE RECEPTOR; PROTEIN RASD1;

ARTICLE; BIOINFORMATICS; CELL STRAIN MCF 7; COMPUTER PROGRAM; CORRELATION ANALYSIS; DRUG RESEARCH; GENE EXPRESSION PROFILING; GENE MAPPING; GENETIC DATABASE; HELODERMA SUSPECTUM; HUMAN; HUMAN CELL; LIZARD; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; UPREGULATION; ANIMAL; BIOLOGY; DRUG DEVELOPMENT; DRUG POTENTIATION; GENETICS; ISOLATION AND PURIFICATION; METABOLISM; METHODOLOGY; NON INSULIN DEPENDENT DIABETES MELLITUS; BIOLOGICAL ACTIVITY; CONNECTIVITY MAPPING ALGORITHM; GENETIC ALGORITHM; GENETIC ANALYSIS; GENETIC SIMILARITY; RNA ANALYSIS; AGONISTS; DIABETES MELLITUS, TYPE 2; MCF 7 CELL LINE; PROCEDURES;

ANIMALIA; HELODERMA SUSPECTUM; HELODERMATIDAE;

ACTIVATING TRANSCRIPTION FACTOR 3; ANIMALS; BIOSIMILAR PHARMACEUTICALS; COMPUTATIONAL BIOLOGY; DIABETES MELLITUS, TYPE 2; DNA-BINDING PROTEINS; DRUG DISCOVERY; EARLY GROWTH RESPONSE PROTEIN 1; HUMANS; HYPOGLYCEMIC AGENTS; INTERLEUKIN-8; LIZARDS; MCF-7 CELLS; PEPTIDES; RAS PROTEINS; RECEPTORS, GLUCAGON; RECEPTORS, STEROID; RECEPTORS, THYROID HORMONE; THIAZOLIDINEDIONES; VENOMS;

EID: 84878499462     PISSN: 00410101     EISSN: 18793150     Source Type: Journal    
DOI: 10.1016/j.toxicon.2013.03.018     Document Type: Article

References (30)

1. Chau H.N., Roth F.P. Discovering the targets of drugs via computational systems biology. J. Bio. Chem. 2011, 286:23653-23658.
2. Chen M.H., Yang W.L., Lin K.T., Liu C.H., Liu Y.W., Huang K.W., Chang P.M.H., Lai J.M., Hsu C.N., Chao K.M., Kao C.Y., Huang C.Y. Gene expression-based chemical genomics identifies potential therapeutic drugs in hepatocellular carcinoma. PLoS ONE 2011, 6:e27186.
3. Cruz L.J., Gray W.R., Olivera B.M. Purification and properties of a myotoxin from Conus geographus venom. Arch. Biochem. Biophys. 1978, 190:539-548.
4. Dragulev B., Bao Y., Ramos-Cerrillo B., Vazques H., Olvera A., Stock R., Algaron A., Fox J.W. Upregulation of IL-6, IL-8, CXCL1 and CXCL2 domainated gene expression in human fibroblast cells exposed to Loxosceles reclusa sphingomyelinase D: insights into spider venom dermonecrosis. J. Invest. Dermatol. 2007, 127:1264-1266.
5. Eng J., Kleinman W.A., Singh L., Singh G., Raufman J.R. Isolation and characterization of exendin-4, and exendin-3 analogue, from Heloderma suspectum venom. J. Biol. Chem. 1992, 267:7402-7405.
6. Fox J.W. Insights into venom and toxin activities and pharmacological/therapeutic potential using gene expression profiling. Toxins and Hemostasis; from Bench to Bedside 2011, 73-81. Springer, NY. USA. R.M. Kini (Ed.).
7. Fox J.W., Serrano S.M.T. Approaching the golden age of natural product pharmaceuticals from venom libraries: an overview to toxins and toxin-derivatives currently involved in therapeutic or diagnostic applications. Curr. Pharma. Des. 2007, 13:2927-2934.
8. Gallagher P.G., Bao Y., Serrano S.M., Kamiguti A.S., Theakston R.D., Fox J.W. Use of microarrays for investigating the subtoxic effects of snake venoms: insights into venom-induced apoptosis in human umbilical vein endothelial cells. Toxicon 2003, 41:429-440.
9. Gallagher P., Bao Y., Serrano S.M., Laing G.D., Theakston R.D., Gutierrez J.M., Escalante T., Zingrino P., Moura-da-Silva A.M., Nischt R., Mauch C., Moskaluk C., Fox J.W. Role of the snake venom toxin jararhagin in proinflammatory pathogenesis: invitro and invivo gene expression analysis of the effects of the toxin. Arch. Biochem. Biophys. 2005, 441:1-15.
10. Koh C.Y., Kini R.M. From snake venom toxins to therapeutics - cardiovascular examples. Toxicon 2011, 15:497-506.
11. Kohn A.J. Cone shell stings; recent cases of human injury due to venomous marine snails of the genus Conus. Hawaii Med. J. 1958, 17:528-532.
12. Koliaki C., Doupis J. Incretin-based therapy: a powerful and promising weapon in the treatment of type 2 diabetes mellitus. Diabetes Ther. 2011, 2:101-121.
13. Kwok H.F., Chen T., O'Rourke M., Ivanyi C., Hirst D., Shaw C. A new bradykinin B2 receptor antagonist decapeptide from lizard venom. Peptides 2008, 29:65-72.
14. Lamb J. The connectivity map; a new tool for biomedical research. Nat. Rev. Cancer 2007, 7:54-60.
15. Lamb J., Crawford E.D., Peck D., Modell J.W., Blat I.C., Wrobel M.J., Lerner J., Brunet J.P., Subramanian A., Ross K.N., Reich M., Hieronymus H., Wei G., Armstrong S.A., Haggarty S.J., Clemons P.A., Wei R., Carr S.A., Lander E.S., Golub T.R. The connectivity map: using gene-expression signatures to connect small molecules, genes, and disease. Science 2006, 323:1929-1935.
16. Lewis R.J., Garcia M.L. Therapeutic potential of venom peptides. Nat. Rev. Drug Discov. 2003, 2:790-802.
17. Markland F.S., Swenson S. Fibrolase: trials and tribulations. Toxins 2010, 2:793-808.
18. McIntosh J.M., Olivera B.M., Cruz L.J., Gray W.R. Gamma-carboxyglutamate in a neuroactive toxin. J. Biol. Chem. 1984, 259:14343-14346.
19. Olivera B.M., Gray W.R., Zeikus R., McIntosh J.M., Varga J., Rivier J., de Santos V., Cruz L.J. Peptide neurotoxins from fish-hunting cone snails. Science 1985, 230:1338-1343.
20. Pachiappan A., Thwin M.M., Manikandan J., Gopalakrishnakone P. Glial inflammation and neurodegeneration induced by candoxin, a novel neurotoxin from Bungarus candidus venom: global gene expression analysis using microarray. Toxicon 2005, 46:883-899.
21. Perchuć A.M., Menin L., Stöcklin R., Buhler B., Schöni R. Pathophysiol. Haemost. Thromb. 2005, 34:241-245.
22. Pinto A.F., Dragulev B., Guimaraes J.A., Fox J.W. Novel perspectives on the pathogenesis of Lonomia obliqua caterpillar envenomation based on assessment of host response by gene expression analysis. Toxicon 2008, 51:1119-1128.
23. Preston C.A. Hypotension, myocardial infarction, and coagulopathy following Gila monster bite. J. Emerg. Med. 1989, 7:37-40.
24. Reka A.K., Kuick R., Kurapati H., Standifor T.J., Omenn G.S., Keshamouni V.G. Identifying inhibitors of epithelial-mesenchymal transition by connectivity map-based systems approach. J. Thor. Onco. 2011, 6:1784-1792.
25. Russell F.E. Snake Venom Poisoning 1980, 214. Scholium International, Great Neck, NY.
26. Schmidtko A., Lotsch J., Freynhagen R., Geisslinger G. Ziconotide for treatment of severe chronic pain. Lancet 2010, 375:1569-1577.
27. Swenson S., Markland F.S. Snake venom fibrin (ogen) olytic enzymes. Toxicon 2005, 45:1021-1039.
28. Teichert R.W., Olivera B.M. Natural products and ion channel pharmacology. Future Med. Chem. 2010, 2:731-744.
29. White M.F. IRS proteins and the common path to diabetes. Am. J. Phys. Endocrin. Met. 2011, 283:413-422.
30. Zhang Y., Wang L., Zhou M., Zhou Z., Chen X., Chen T., Kwok H.F., Ivanyi C., Shaw C. The structure of helokinestatin-5 and its biosynthetic precursor from Gila monster (Heloderma suspectum) venom: evidence for helokinestatin antagonism of bradykinin-induced relaxation of rat tail artery smooth muscle. Peptides 2010, 31:1555-1561.